<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124601</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-7HJ</org_study_id>
    <secondary_id>2019-003865-17</secondary_id>
    <nct_id>NCT04124601</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer</brief_title>
  <acronym>CHINOREC</acronym>
  <official_title>Neoadjuvant CHemoradiotherapy With Sequential Ipilimumab and NivOlumab in RECtal Cancer (CHINOREC): a Prospective Randomized, Open-label, Multicenter, Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Laengle, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized, open-label, multicenter, phase II clinical trial investigates
      the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential
      ipilimumab and nivolumab in rectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Incidence of treatment-emergent adverse events will be assessed according to the latest &quot;Clavien- Dindo Classification of surgical complications&quot; and Common Terminology Criteria of Adverse Events (CTCAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic therapy response between pre-and post-neoadjuvant treatment</measure>
    <time_frame>20 weeks</time_frame>
    <description>Radiographic therapy response will be determined by magnetic resonance imaging-assessed tumor regression grade (mrTRG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic therapy response to neoadjuvant treatment</measure>
    <time_frame>20 weeks</time_frame>
    <description>Pathological therapy response will be determined according to the latest American Joint Committee on Cancer/International Union Against Cancer-Tumor Node Metastasis (AJCC/UICC-TNM) staging and tumor regression grade (TRG).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemoradiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemoradiotherapy, Ipilimumab, Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant Chemoradiotherapy (50 Gy in 2 Gy fractions + Capecitabine 1650 mg/m2/d over 25 working days) with sequential Ipilimumab (1 mg/kg IV on day 7) and Nivolumab (3 mg/kg IV on day 14, 28 and 42)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiotherapy</intervention_name>
    <description>Capecitabine tablet with fractionated radiotherapy</description>
    <arm_group_label>Neoadjuvant Chemoradiotherapy</arm_group_label>
    <arm_group_label>Neoadjuvant Chemoradiotherapy, Ipilimumab, Nivolumab</arm_group_label>
    <other_name>Radiochemotherapy</other_name>
    <other_name>Chemoradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Neoadjuvant Chemoradiotherapy, Ipilimumab, Nivolumab</arm_group_label>
    <other_name>Yervoy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Neoadjuvant Chemoradiotherapy, Ipilimumab, Nivolumab</arm_group_label>
    <other_name>Opdivo®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older

          -  All sexes

          -  Histologically confirmed carcinoma of the rectum

          -  Suitable for local therapy with curative intent

          -  Medical need for a standard neoadjuvant CRT

          -  Suitable to withstand a course of standard neoadjuvant CRT

          -  Written informed consent form (ICF) for participation in the study

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Metastatic disease that is considered incurable by local therapies

          -  Previous surgery of the tumor other than biopsy

          -  Pregnancy, breastfeeding or expectancy to conceive

          -  Disagreement of participants with reproductive potential to use contraception
             throughout the study period and for up to 180 days after the last dose of study
             therapy

          -  Prior therapy with anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-PD-L2 or any other agent
             directed against co-inhibitory T cell receptors or has previously participated in
             clinical studies with immunotherapy

          -  Any contraindication according to the official medical information of Ipilimumab or
             Nivolumab

          -  Live vaccine within 30 days prior to the first dose of study therapy

          -  Hepatitis B or C

          -  Human immunodeficiency virus (HIV)

          -  Immunodeficiency

          -  Allogeneic tissue or solid organ transplantation

          -  Autoimmune disease that has required systemic therapy in the past 2 years with
             modifying agents, steroids or immunosuppressive drugs

          -  Systemic steroids or any other form of immunosuppressive therapy within 7 days prior
             to the first dose of study treatment

          -  Active non-infectious pneumonitis

          -  Active infection requiring systemic therapy

          -  Diagnosed and/or treated additional malignancy within 5 years of randomization, with
             the exception of curatively-treated basal cell or squamous cell carcinoma of the skin
             and/or curatively-resected in situ cervical and/or breast cancers

          -  Treatment with botanical preparations (i.e. herbal supplements or traditional Chinese
             medicines) intended for general health support or to treat the disease under study
             within 2 weeks prior to randomization/treatment

          -  Participants with serious or uncontrolled medical disorders

          -  Uncontrolled or significant cardiovascular disease (myocardial infarction,
             uncontrolled angina, any history of clinically significant arrhythmias, QTc
             prolongation in males &gt; 450 ms and &gt; 470 ms in females, participants with history of
             myocarditis)

          -  Allergies and adverse drug reaction (history of allergy or hypersensitivity to study
             drug components, contraindications to any of the study drugs of the chemotherapy
             regimen)

          -  Other exclusion criteria: Prisoners or participants who are involuntarily
             incarcerated, participants who are compulsorily detained for treatment of either a
             psychiatric or physical (i.e. infectious disease) illness

          -  White blood cells &lt; 2000/μL (SI: &lt; 2.00 × 109/L)

          -  Neutrophils &lt; 1500/μL (SI: &lt; 1.50 × 109/L)

          -  Platelets &lt; 100 × 103/μL (SI: &lt; 100 × 109/L) (transfusions not permitted within 72 h
             prior to qualifying laboratory value)

          -  Hemoglobin &lt; 9.0 g/dl (SI: &lt; 90 g/L) (transfusions not permitted within 72 h prior to
             qualifying laboratory value)

          -  Serum creatinine &gt; 1.5 × upper limit of normal (ULN) or calculated creatinine
             clearance &lt; 50 ml/min (using the Cockcroft-Gault formula)

          -  AST/ALT: &gt; 3.0 × ULN

          -  Total bilirubin &gt; 1.5 × ULN (except participants with Gilbert Syndrome who must have a
             total bilirubin level of &lt; 3.0 × ULN)

          -  Troponin T (TnT) or I (TnI) &gt; 2 × institutional ULN. TnT or TnI levels between &gt; 1 to
             2 × ULN will be permitted to participate in the study if a repeat assessment remains 2
             × ULN and participant undergoes a cardiac evaluation. When repeat levels within 24 h
             are not available, a repeat test should be conducted as soon as possible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Bergmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of General Surgery, Department of Surgery, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Laengle, MD, PhD</last_name>
    <phone>+43 1 40400 69260</phone>
    <email>johannes.laengle@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Bergmann, MD</last_name>
    <phone>+43 1 40400 69260</phone>
    <email>michael.bergmann@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>State Hospital Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <state>Lower Austria</state>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Friedrich Laengle, MD</last_name>
      <phone>+43 2622 9004 22201</phone>
      <email>friedrich.laengle@wienerneustadt.lknoe.at</email>
    </contact>
    <investigator>
      <last_name>Friedrich Laengle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of St. John of God</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedrich Herbst, MD</last_name>
      <phone>+43 1 21121 3250</phone>
      <email>friedrich.herbst@bbwien.at</email>
    </contact>
    <investigator>
      <last_name>Friedrich Herbst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Laengle, MD, PhD</last_name>
      <phone>+43 1 40400 69260</phone>
      <email>johannes.laengle@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Michael Bergmann, MD</last_name>
      <phone>+43 1 40400 69260</phone>
      <email>michael.bergmann@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Johannes Laengle, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Bergmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital North - Clinic Floridsdorf</name>
      <address>
        <city>Vienna</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Razek, MD</last_name>
      <phone>+43 1 277000</phone>
      <email>peter.razek@wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Peter Razek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Johannes Laengle, MD, PhD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Ipilimumab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

